<DOC>
	<DOCNO>NCT02216643</DOCNO>
	<brief_summary>Prospective , multi-center , randomize , control , open , blinded-endpoint trial sequential design . The randomization employ 1:1 ratio mechanical thrombectomy stentriever and/or Thromboaspiration versus medical management alone . Randomization do minimization process use age , baseline NIHSS , use IV tpa , vessel occlusion site hospital . To evaluate hypothesis mechanical thrombectomy superior medical management alone achieve favorable outcome distribution modify Rankin Scale score 90 day subject present acute large vessel ischemic stroke &lt; 8 hour symptom onset . Subjects either ineligible IV alteplase receive IV alteplase therapy without recanalization . Sample size project 690 patient difference treatment effect 10 % .</brief_summary>
	<brief_title>EndoVascular Treatment With Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy Acute Ischemic Stroke</brief_title>
	<detailed_description>Patients acute ischemic stroke relate anterior circulation large vessel occlusion randomize 8 hour symptoms onset arm ( mechanical thrombectomy versus medical management alone ) . Subjects either ineligible IV alteplase receive IV alteplase therapy without recanalization . They admit acute stroke unit Brazil ( ICU need ) treat follow international guideline . Concomitant medication non-pharmacological therapy record . A maximum six attempt retrieve thrombus single vessel make . No additional treatment allow either Intrarterial tPA , mechanical device angioplasty/stenting . The primary endpoint distribution modify Rankin Scale score 90 day ( shift analysis ) evaluate two separate assessor blind treatment Interim Analysis The sample size Phase III Trial project 690 subject . For interim analysis , method Lan DeMets use allocate alpha via power family method φ ( phi ) equal 1 assessment efficacy futility , respectively first 174 , 346 518 patient enrol complete 90-day follow-up . The interval may frequent request Data Safety Monitoring Board ( DSMB ) . At interim analysis , case stop boundary cross DSMB may recommend stop study either good efficacy test treatment either futility . Other factor , safety , take consideration DSMB decision stop study . When consider stop trial safety reason , DSMB instruct consider mortality ( mRS=6 ) severe dependency ( mRS=5 ) 3 month one single outcome .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<criteria>1 . Acute ischemic stroke patient ineligible IV thrombolytic treatment treatment contraindicate ( e.g. , subject present beyond recommended time symptom onset ) , patient receive IV thrombolytic therapy without clinical improvement . 2 . No significant prestroke functional disability ( mRS ≤ 1 ) 3 . Baseline NIHSS score obtain prior randomization must equal high 8 point 4 . Age ≥18 year 5 . Occlusion ( TICI 01 ) intracranial ICA ( distal ICA T occlusion ) and/or MCAM1 segment suitable endovascular treatment , evidence CTA , MRA angiogram , without concomitant cervical carotid occlusion stenosis . 6 . Patient treatable within eight hour symptom onset . Symptoms onset define point time patient last see well ( baseline ) . Treatment start define groin puncture . 7 . Informed consent obtain patient acceptable patient surrogate 1 . Known hemorrhagic diathesis , coagulation factor deficiency , oral anticoagulant therapy INR &gt; 3.0 2 . Baseline platelet count &lt; 30.000/µL 3 . Baseline blood glucose &lt; 50mg/dL &gt; 400mg/dl 4 . Severe , sustain hypertension ( SBP &gt; 185 mm Hg DBP &gt; 110 mm Hg ) NOTE : If blood pressure successfully reduce maintain acceptable level use AHA guideline recommend medication ( include iv antihypertensive drip ) , patient enrol . 5 . Patients coma ( NIHSS item consciousness &gt; 1 ) ( Intubated patient transfer could randomize case NIHSS obtain neurologist prior transportation ) . 6 . Seizures stroke onset would preclude obtain baseline NIHSS 7 . Serious , advanced , terminal illness anticipate life expectancy le one year . 8 . History life threaten allergy ( rash ) contrast medium 9 . Subjects receive IV tPA treatment beyond 4,5 hour begin symptom 10 . Woman childbearing potential know pregnant lactate positive pregnancy test admission . 11 . Subject participate study involve investigational drug device would impact study . 12 . Cerebral vasculitis 13 . Patients preexist neurological psychiatric disease would confound neurological functional evaluation , mRS score baseline must ≤1 . This exclude patient severely demented , require constant assistance nursing home type set live home fully independent activity daily live ( toileting , dress , eat , cook prepare meal , etc . ) 14 . Unlikely available 90day followup ( e.g . fix home address , visitor overseas ) . 15 . Hypodensity CT restrict diffusion amount ASPECTS score &lt; 6 NCCT , &lt; 5 DWI MRI . The use CTP MRI perfusion optional . 16 . Collaterals malignant profile CTA ( without colateral circulation CTA ) 17 . CT MR evidence hemorrhage ( presence GRE microbleeds allow ) . 18 . Significant mass effect midline shift . 19 . Evidence ipsilateral carotid occlusion , high grade stenosis arterial dissection extracranial petrous segment internal carotid artery treat prevent access intracranial clot excessive tortuosity cervical vessel preclude device delivery/deployment 20 . Subjects occlusion multiple vascular territory ( e.g. , bilateral anterior circulation , anterior/posterior circulation ) 21 . Evidence intracranial tumor ( except small meningioma ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Ischemic Stroke</keyword>
	<keyword>Thrombectomy</keyword>
	<keyword>Reperfusion Therapy</keyword>
	<keyword>Treatment</keyword>
</DOC>